Diroximel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators.
Journal: ACS chemical neuroscience
Published: July 07, 2026
Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.
Journal: Clinical immunology (Orlando, Fla.)
Published: July 07, 2026
Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation.
Journal: PloS one
Published: April 11, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes.
Journal: Advances in therapy
Published: February 13, 2026
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Multiple sclerosis and related disorders
Published: December 12, 2025
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.
Journal: Advances in therapy
Published: October 23, 2025
Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.
Journal: International journal of molecular sciences
Published: October 16, 2025
Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.
Journal: Neurodegenerative disease management
Published: October 07, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Effect of diroximel fumarate on gut dysbiosis and autoimmunity in the central nervous system.
Journal: International immunopharmacology
Published: August 22, 2025
Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways.
Journal: Journal of neuroinflammation
Published: July 18, 2025
Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 22, 2025
Last Updated: 09/26/2026